Interesting ImagesPosttreatment FDG-Avid Splenic Lesions in DLBCL and HD Clinical and Radiographic Characteristics for Risk AssessmentNachmias, Boaz MD, PhD∗; Godefroy, Jeremy MD†; Rozenbach, Eyal MD†; Ganzel, Chezi MD‡; Bar-Shalom, Rachel MD§; Goldschmidt, Neta MD∗; Vainstein, Vladimir MD∗Author Information From the Departments of ∗Hematology †Nuclear Medicine, Hadassah Medical Center Departments of ‡Hematology §Nuclear Medicine, Shaare Zedek Medical Center, Jerusalem, Israel. Received for publication November 18, 2019; revision accepted March 6, 2020. Boaz Nachmias and Jeremy Godefroy are equal contributors. Conflicts of interest and sources of funding: none declared. Data were collected in accordance with the Declaration of Helsinki, and the study was approved by the institutional human research committee. Correspondence to: Boaz Nachmias, MD, PhD, Department of Hematology, Hadassah Medical Center, Kyriat Hadassah, PO Box 12000, Jerusalem, Israel. E-mail: Nachmiasb@gmail.com. Clinical Nuclear Medicine: July 2020 - Volume 45 - Issue 7 - p 542-544 doi: 10.1097/RLU.0000000000003052 Buy Metrics Abstract Residual end of treatment (EOT) FDG-avid lesions are often due to infectious or inflammatory process and not due to refractory lymphoma. Nonetheless, such lesions prompt diagnostic and therapeutic interventions. We evaluate clinical and radiological characteristics of patients with EOT FDG-avid splenic lesions. Comparing metabolic volume (MV) ratio between EOT to interim, showed a marked difference between false positive and true positive lesions (0.5 vs 3.6, P = 0.02). EOT SUVmax was also significantly different between the groups (7 vs. 19, P = 0.02). We suggest EOT/interim-MV ratio as a tool to identify patients at low risk of refractory disease allowing non-invasive surveillance. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.